Panelists discuss how future directions in multiple myeloma include exciting developments like bispecific T-cell engagers (BiTEs) targeting B-cell maturation antigen (BCMA) and GPRC5D, dual-target ...
Clinical Trials Arena on MSN
IMS26: Key readouts rock the multiple myeloma field amid shifting landscape
Data from AbbVie, J&J and BMS grabbed the attention of IMS 2026 attendees as the pharma titans battle for market share in the ...
Revolutions in transplantation and targeted and immune therapies have transformed multiple myeloma from a disease with an associated survival of a few years into one for which functional cure is an ...
A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a ...
Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results